WO2000030611A2 - Pharmazeutisches präparat - Google Patents
Pharmazeutisches präparat Download PDFInfo
- Publication number
- WO2000030611A2 WO2000030611A2 PCT/EP1999/009039 EP9909039W WO0030611A2 WO 2000030611 A2 WO2000030611 A2 WO 2000030611A2 EP 9909039 W EP9909039 W EP 9909039W WO 0030611 A2 WO0030611 A2 WO 0030611A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- preparation according
- derivative
- procaine
- lipid vesicles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a pharmaceutical preparation that contains diminazene diacetate and procaine or a procaine derivative.
- Trypanozides based on diminazen are known as chemotherapeutic agents, which are available in powder form, so that the solution for injection still has to be mixed before the injection, or which are already in the form of an aqueous solution, sometimes using solubilizers to obtain stable solutions.
- Diminazen-di-aceturate-containing preparations are also combined with procaine or lidocaine to suppress pain conditions during the injection.
- a new outbreak of the disease can occur in the course of a few months without a new infection being present, so that it can be assumed that not all pathogens which, for. B. are partially in organs and are also in various stages of development, can be safely killed.
- a pharmaceutical preparation which contains diminazene diacetate and procain or a procaine derivative, which is in the form of a suspension of lipid vesicles (liposomes), the aforementioned active substances being enclosed inside the lipid vesicles.
- the preparation according to the invention is administered by injection and is suitable for the veterinary and human medical fields.
- the lipid vesicles are produced by the known methods, the suspensions obtained being further processed by dialysis or another suitable method, so that the desired active compounds are only present in the lipid vesicles.
- the active ingredients can also be present in the aqueous solution which surrounds the lipid vesicles, so that dialysis or the like is not necessary from this point of view.
- Phospholipids and glycolipids are used to produce the lipid vesicles. These are preferably stearylamine (SA), cholesterol (Chol) and phosphatidylcholine (PC), which are also preferably used in combination in a ratio of 5: 1: 1.
- the embodiment of the preparation according to the invention in the form of a suspension with lipid vesicles (liposomes) is particularly advantageous, since these can fuse with the plasma membrane of different body cells and thereby infiltrate non-permeable substances into cells. It can even be assumed that the blood-brain barrier can be overcome in this way, so that appropriate pathogens can be killed even there.
- diminazene diacetate in addition to diminazene diacetate or instead, pentamidine can be used as the active ingredient.
- the combination of diminazenediacetate and pentamidine is particularly advantageous, since some of these have a different spectrum of activity and thus complement one another, so that almost all types of blood parasites are detected.
- the preparation also contains phenazone, which acts as an analgesic, thereby alleviating pain and fever conditions which are caused by the injection or infection and which occur in protozoan infections such as malaria and trypanomiasis.
- This active ingredient need not be included in the lipid vesicles.
- Procaine or lidocaine which can be used instead of or together with procaine, and the corresponding derivatives serve to lower the high fever associated with protozoan infection and to avoid the severe pain that may result from the injection, which can lead to fatal shock conditions can.
- Acetylsalicylic acid or a derivative can also be used as a fever and pain reliever.
- the preparation according to the invention contains isometadium hydrochloride from the group of phenathridines or nitronidazole as a further biocidal active ingredient, which can be present in the preparation or the lipid vesicles in addition or as an alternative to pentamidine and / or diminazene diacetate.
- a particularly preferred embodiment consists of the preparation or the lipid vesicles additionally containing penicillin or a penicillin derivative, such as procain-benzylpenicillinate, since this prolongs the duration of action of the penicillin.
- penicillin the organism of infected people and animals can also fight other pathogens from secondary infections, which can otherwise also lead to death.
- tetracycline preferably 10%, which is also effective against anaplosmosis, is also particularly advantageous.
- antibiotic substances such as nisin can also be used.
- a solubilizer preferably a cellulose ether with or without glycerol, can be contained in the preparation in order to b Bring partially insoluble substances against protozoa into solution.
- Piroplasmosis (Piroplasma motasi, Piroplasma caballi) Babesiosis (Babesia bigemina, Babesia motasi, Babesia canis and other Babesia)
- Plasmodium vivax Plasmodium malaria
- Plasmodium falciparum Plasmodium ovalae
- Preferred embodiments of the preparation according to the invention have the following compositions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22798/00A AU2279800A (en) | 1998-11-24 | 1999-11-23 | Pharmaceutical preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853937.1 | 1998-11-24 | ||
DE19853937A DE19853937A1 (de) | 1998-11-24 | 1998-11-24 | Pharmazeutisches Präparat |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000030611A2 true WO2000030611A2 (de) | 2000-06-02 |
WO2000030611A3 WO2000030611A3 (de) | 2000-08-31 |
Family
ID=7888688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/009039 WO2000030611A2 (de) | 1998-11-24 | 1999-11-23 | Pharmazeutisches präparat |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2279800A (de) |
DE (1) | DE19853937A1 (de) |
WO (1) | WO2000030611A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004105772A1 (de) | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten |
WO2008016300A2 (en) * | 2006-08-03 | 2008-02-07 | Prosensa Technologies B.V. | Antibiotic composition |
CN102636582A (zh) * | 2011-11-30 | 2012-08-15 | 河北科星药业有限公司 | 测定三氮脒颗粒中三氮脒和安替比林含量的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0006752A1 (de) * | 1978-06-28 | 1980-01-09 | Merck & Co. Inc. | Arzneimittel zur Behandlung chronischer Trypanosomiasis-Infektionen |
EP0193414A2 (de) * | 1985-03-01 | 1986-09-03 | David John Fluck | Liposome, Verfahren zu deren Herstellung und sie enthaltende Mittel |
DE4309415A1 (de) * | 1993-03-19 | 1994-09-22 | Alan Jacques Bourdichon | Pharmazeutisches Präparat |
WO1997006769A2 (de) * | 1995-08-21 | 1997-02-27 | Bourdichon Alain Jacques | Pharmazeutisches präparat mit trypanoziden eigenschaften enthaltend diminazen, pentamidin und phenazon |
WO1998017266A2 (de) * | 1996-10-18 | 1998-04-30 | Atarost Allgem. Tierarzneimittelfabrik, Dr. Ulrich Böhmer, Nachf. Gmbh & Co. | Pharmazeutisches präparat enthaltend amidinderivat und procain |
-
1998
- 1998-11-24 DE DE19853937A patent/DE19853937A1/de not_active Withdrawn
-
1999
- 1999-11-23 AU AU22798/00A patent/AU2279800A/en not_active Abandoned
- 1999-11-23 WO PCT/EP1999/009039 patent/WO2000030611A2/de active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0006752A1 (de) * | 1978-06-28 | 1980-01-09 | Merck & Co. Inc. | Arzneimittel zur Behandlung chronischer Trypanosomiasis-Infektionen |
EP0193414A2 (de) * | 1985-03-01 | 1986-09-03 | David John Fluck | Liposome, Verfahren zu deren Herstellung und sie enthaltende Mittel |
DE4309415A1 (de) * | 1993-03-19 | 1994-09-22 | Alan Jacques Bourdichon | Pharmazeutisches Präparat |
WO1997006769A2 (de) * | 1995-08-21 | 1997-02-27 | Bourdichon Alain Jacques | Pharmazeutisches präparat mit trypanoziden eigenschaften enthaltend diminazen, pentamidin und phenazon |
WO1998017266A2 (de) * | 1996-10-18 | 1998-04-30 | Atarost Allgem. Tierarzneimittelfabrik, Dr. Ulrich Böhmer, Nachf. Gmbh & Co. | Pharmazeutisches präparat enthaltend amidinderivat und procain |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004105772A1 (de) | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten |
WO2008016300A2 (en) * | 2006-08-03 | 2008-02-07 | Prosensa Technologies B.V. | Antibiotic composition |
WO2008016300A3 (en) * | 2006-08-03 | 2008-04-24 | Prosensa Bv | Antibiotic composition |
CN101511430A (zh) * | 2006-08-03 | 2009-08-19 | 普罗森萨技术有限公司 | 抗生素组合物 |
CN102636582A (zh) * | 2011-11-30 | 2012-08-15 | 河北科星药业有限公司 | 测定三氮脒颗粒中三氮脒和安替比林含量的方法 |
Also Published As
Publication number | Publication date |
---|---|
DE19853937A1 (de) | 2000-05-25 |
WO2000030611A3 (de) | 2000-08-31 |
AU2279800A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69900249T2 (de) | Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie | |
DE69224080T2 (de) | Verwendung von nsaid zur behandlung von demenz | |
DE60016602T2 (de) | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel | |
DE69921662T2 (de) | Verwendung von gingko biloba extrakten zur herstellung eines arzneimittels zur behandlung der amyotrophen lateralsklerose | |
DE2802273B2 (de) | Verfahren zur Herstellung von Suppositorien aus Aminoglycid-Antibiotica | |
WO2000030611A2 (de) | Pharmazeutisches präparat | |
DE60206169T2 (de) | Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff | |
DE60003175T2 (de) | Kombinationspräparat zur behandlung von malaria | |
DE19530708C2 (de) | Pharmazeutisches Präparat mit trypanoziden Eigenschaften | |
EP1220668B1 (de) | Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria | |
DE2820991C2 (de) | ||
EP2136816B1 (de) | Oleylphosphocholin | |
DE60212842T2 (de) | Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten | |
DE3851389T2 (de) | Liposom-Freisetzungssystem für Opoid-Analgetika. | |
EP1638577B1 (de) | Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat | |
DE4220616C2 (de) | Dexniguldipin zur intravenösen Verabreichung | |
WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
DE4236069A1 (de) | Arzneimittel, insbesondere für orale Einnahme | |
DE3043909A1 (de) | Arzneimittel, enthaltend eine kombination von acetylsalicylsaeure und heptaminol | |
DE19854139A1 (de) | Pharmazeutisches Präparat mit trypanoziden und blutschizontoziden Eigenschaften | |
DE19854143A1 (de) | Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung | |
DE2265235A1 (de) | Heilmittel | |
WO2007147772A1 (de) | Mittel gegen malaria | |
DE69018359T2 (de) | Amphotericin-B-Lipidkomplex. | |
DE4023136A1 (de) | Neue galenische, orale form zur verbesserung der bioverfuegbarkeit von medikamenten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999966900 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999966900 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |